EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)ÄquivalenzstudieOpen Access

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

April C Pettit iD, Patrick P J Phillips, Ekaterina Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson, Kelly E Dooley, Ian Sanne, Ziyaad Waja, Lerato Mohapi, Anthony T Podany, Wadzanai Samaneka und 11 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac707 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von April C Pettit und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Tuberculosis, HIV Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis (TB) Trials Consortium Study 31/AIDS Clinical Trials Group A5349, an international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen substituting rifapentine for rifampin and moxifloxacin for ethambutol had noninferior efficacy and was safe for the treatment of drug-susceptible pulmonary TB (DS-PTB) compared with the standard 6-month regimen. We explored results among the prespecified subgroup of people with human immunodeficiency virus (HIV) (PWH).

Methods

PWH and CD4+ counts ≥100 cells/μL were eligible if they were receiving or about to initiate efavirenz-based antiretroviral therapy (ART). Primary endpoints of TB disease-free survival 12 months after randomization (efficacy) and ≥ grade 3 adverse events (AEs) on treatment (safety) were compared, using a 6.6% noninferiority margin for efficacy. Randomization was stratified by site, pulmonary cavitation, and HIV status. PWH were enrolled in a staged fashion to support cautious evaluation of drug–drug interactions between rifapentine and efavirenz.

Results

A total of 2516 participants from 13 countries in sub-Saharan Africa, Asia, and the Americas were enrolled. Among 194 (8%) microbiologically eligible PWH, the median CD4+ count was 344 cells/μL (interquartile range: 223–455). The rifapentine-moxifloxacin regimen was noninferior to control (absolute difference in unfavorable outcomes −7.4%; 95% confidence interval [CI] −20.8% to 6.0%); the rifapentine regimen was not noninferior to control (+7.5% [95% CI, −7.3% to +22.4%]). Fewer AEs were reported in rifapentine-based regimens (15%) than the control regimen (21%).

Conclusions

In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe. Clinical Trials Registration NCT02410772.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, PulmonaryTuberculosisHIV InfectionsHumansRifampinMoxifloxacinAntitubercular AgentsHIVIsoniazidDrug Therapy, CombinationAlkynesCyclopropanesBenzoxazines

Stichwörter der Autor:innen

human immunodeficiency virusmoxifloxacinphase 3 clinical trialrifapentinetuberculosis

Substanzen

RifampinMoxifloxacinAntitubercular AgentsIsoniazidrifapentineefavirenzAlkynesCyclopropanesBenzoxazines

Autor:innen und Institutionen

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
  • Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Center for TB Research Innovation, University of Cape Town Lung Institute, Cape Town, South Africa.
  • Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Clinical HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: April C Pettit

Förderung

  • NIAID NIH HHS
  • Centers for Disease Control and Prevention
  • National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
  • Division of Tuberculosis Elimination
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Case Western Reserve University
  • Sanofi

Zitieren

APA

Pettit, A. C., Phillips, P. P. J., Kurbatova, E., Vernon, A., Nahid, P., Dawson, R., Dooley, K. E., Sanne, I., Waja, Z., Mohapi, L., Podany, A. T., Samaneka, W., Savic, R. M., Johnson, J. L., Muzanyi, G., Lalloo, U. G., Bryant, K., Sizemore, E., Scott, N., …, & Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team (2023). Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac707

Vancouver

Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, et al. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac707

BibTeX
@article{Pettit2023,
  author = {Pettit, April C and Phillips, Patrick P J and Kurbatova, Ekaterina and Vernon, Andrew and Nahid, Payam and Dawson, Rodney and Dooley, Kelly E and Sanne, Ian and Waja, Ziyaad and Mohapi, Lerato and Podany, Anthony T and Samaneka, Wadzanai and Savic, Rada M and Johnson, John L and Muzanyi, Grace and Lalloo, Umesh G and Bryant, Kia and Sizemore, Erin and Scott, Nigel and Dorman, Susan E and Chaisson, Richard E and Swindells, Susan and Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team, Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team},
  title = {Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac707}
}
Kostenlos starten →